Senior Director, Biostatistics – Rare Diseases Strategy

Ipsen Biopharmaceuticals Inc.; Cambridge (MA); On-site; USD 180,000 - 240,000; Full time

Job summary

Ipsen Biopharmaceuticals Inc. in the United States seeks a Senior Director of Biostatistics for Rare Diseases to provide program-level statistical leadership across assets and mentoring for a biostatistics team.

You will collaborate with cross-functional partners, engage with regulatory authorities, ensure data integrity, and contribute to development plans and regulatory submissions, while shaping analytics strategy and advancing patient outcomes in rare diseases.

Qualifications

• Lead and mentor a team of biostatisticians.
• Provide program- and project-level statistical leadership for rare disease assets.
• Engage with regulatory agencies and academic institutions to align with standards.
• Ensure data integrity and regulatory compliance.

Responsibilities

• Lead program-level biostatistician in cross-functional teams; author study documents such as SAPs and CSRs.
• Provide strategic leadership within rare disease programs.
• Coordinate planning and execution of biostatistics deliverables with internal and CRO teams.
• Ensure accuracy, precision and robustness in planning, design and analysis of trials.
• Support regulatory documents and scientific publications; internal ad-hoc analyses.
• Mentor and develop team; contribute to departmental strategy.
• Lead cross-functional initiatives like data strategy and process optimization.

Skills

Biostatistics leadership

Statistical analysis

Regulatory submission

Job description

Ipsen Biopharmaceuticals Inc. in the United States seeks a Senior Director of Biostatistics for Rare Diseases to provide program-level statistical leadership across assets and mentoring for a biostatistics team.

You will collaborate with cross-functional partners, engage with regulatory authorities, ensure data integrity, and contribute to development plans and regulatory submissions, while shaping analytics strategy and advancing patient outcomes in rare diseases.